In this episode of CardiaCast, hypertrophic cardiomyopathy (HCM) expert Dr. Matthew Martinez will discuss with Dr. Michelle Kittleson recommendations for early diagnosis in the 2024 HCM guideline and review the latest clinical and real-world trial data for new (mavacamten) and emerging (aficamten) cardiac myosin inhibitors.

This CardiaCast is part of an educational series, "2024 Update to the AHA/ACC HCM Guideline: Expert Interpretation for Application to Practice," which includes a total of three ACC CardiaCasts and an accredited #MedX. The series is produced by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Bristol Myers Squibb. Exploring HCM Diagnosis and Treatment Options: The New Frontier of Cardiac Myosin Inhibitors (acc.org)

Suggested Materials:

1. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759-69. Erratum in: Lancet 2020;396:758.

1. Desai MY, Owens A, Wolski K, et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol 2023;8:968-77.

1. Maron MS, Masri A, Nassif ME, et al; SEQUOIA-HCM Investigators. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 2024;390:1849-61.